1. Home
  2. Labeler Index
  3. A-s Medication Solutions
  4. 50090-4214
  5. Product Images: Fluticasone Propionate And Salmeterol Diskus

Product Images Fluticasone Propionate And Salmeterol Diskus

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 16 images provide visual information about the product associated with Fluticasone Propionate And Salmeterol Diskus NDC 50090-4214 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

fluticasone propionate chemical structure - fp sal spl graphic 01

fluticasone propionate chemical structure - fp sal spl graphic 01

salmeterol xinafoate chemical structure - fp sal spl graphic 02

salmeterol xinafoate chemical structure - fp sal spl graphic 02

Figure 1. Mean Percent Change From Baseline in FEV1 in Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 03

Figure 1. Mean Percent Change From Baseline in FEV1 in Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 03

This text represents a chart that shows the results of a study on the change in FEV (Forced Expiratory Volume) from baseline levels. The study compares the effects of Fluticasone propionate/salmeterol 100/50 meg twice daily, Fluticasone propionate 100 mog twice daily and Saimeterol 50 mog twice daily on the subjects' FEV levels. The chart shows a 0.5% increase in FEV for the Fluticasone propionate/salmeterol 100/50 meg group, a 0.2% increase for the Fluticasone propionate 100 mog group, and a 0.7% increase for the Saimeterol 50 mog group, all as compared to placebo.*

Figure 2. Percent Change in Serial 12-hour FEV1 in Subjects With Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 04

Figure 2. Percent Change in Serial 12-hour FEV1 in Subjects With Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 04

The text presents a graph showing a 9% change in FEV4, with four treatment options labeled: Fluticasone propionate/salmeterol 100/50 mog twice daily, Salmeterol 50 meg twice daily, Fluticasone propionate 100 meg twice daily, and Placebo. The treatments are represented by four lines with different colors. The graph also shows the baseline of the measurement taken on day 1.*

Figure 3. Percent Change in Serial 12-hour FEV1 in Subjects With Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 05

Figure 3. Percent Change in Serial 12-hour FEV1 in Subjects With Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 05

This appears to be a chart or graph showing the results of a study comparing the effects of different medications on percent change in FEV (forced expiratory volume) over time. The medications being compared are Fluticasone propionate/salmeterol, Salmeterol, Fluticasone propionate, and a Placebo. The chart shows the data for the study participants over a period of 12 weeks. This chart does not provide enough information to allow for further interpretation or conclusions.*

Figure 4. Predose FEV1: Mean Percent Change From Baseline in Subjects With Chronic Obstructive Pulmonary Disease - fp sal spl graphic 06

Figure 4. Predose FEV1: Mean Percent Change From Baseline in Subjects With Chronic Obstructive Pulmonary Disease - fp sal spl graphic 06

The text is describing a clinical trial for asthma medication. The trial involved three groups: one group took 38 doses of fluticasone propionate/salmeterol 250/50 mcg twice daily with a baseline forced expiratory volume (FEV) of 1207 mL, another group took salmeterol 50 mcg twice daily with a baseline FEV of 1205 mL, and a third group was given a placebo with a baseline FEV of 1232 mL. The graph shows the change in FEV over time for each group, with the fluticasone propionate/salmeterol group having the greatest improvement in FEV compared to the other two groups.*

Figure 5. Two-Hour Postdose FEV1: Mean Percent Changes From Baseline Over Time in Subjects With Chronic Obstructive Pulmonary Disease - fp sal spl graphic 07

Figure 5. Two-Hour Postdose FEV1: Mean Percent Changes From Baseline Over Time in Subjects With Chronic Obstructive Pulmonary Disease - fp sal spl graphic 07

This is a table displaying the results of a clinical trial comparing the efficacy of two doses of Fluticasone propionate/salmeterol and placebo as a treatment for a respiratory condition. The results are based on the baseline Forced Expiratory Volume (FEV, measured in milliliters) of the participants. The table shows the number of participants (N) and their results at different time points (Day1, Week, and Endpoint) for each treatment group.*

Figure A - fp sal spl graphic 08

Figure A - fp sal spl graphic 08

Figure B - fp sal spl graphic 09

Figure B - fp sal spl graphic 09

Figure C - fp sal spl graphic 10

Figure C - fp sal spl graphic 10

IFU Figure D - fp sal spl graphic 11

IFU Figure D - fp sal spl graphic 11

Figure E - fp sal spl graphic 12

Figure E - fp sal spl graphic 12

Figure F - fp sal spl graphic 13

Figure F - fp sal spl graphic 13

IFU Figure G - fp sal spl graphic 14

IFU Figure G - fp sal spl graphic 14

Figure H - fp sal spl graphic 15

Figure H - fp sal spl graphic 15

Label Image - lbl500904214

Label Image - lbl500904214

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.